loading page

Evaluation of intestinal permeability using serum biomarkers in Learning Early About Peanut allergy trial
  • +9
  • Ozge Nur Aktas,
  • Allyson Mateja,
  • Min (Jenny) Li,
  • Lindsay Chatman,
  • Megan C. Grieco,
  • Carolyn H. Baloh,
  • Michelle F Huffaker,
  • Lisa Wheatley,
  • George Du Toit,
  • Gideon Lack,
  • Erica Brittain,
  • Pamela Guerrerio
Ozge Nur Aktas
National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases

Corresponding Author:[email protected]

Author Profile
Allyson Mateja
National Cancer Institute Frederick National Laboratory for Cancer Research
Author Profile
Min (Jenny) Li
National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases
Author Profile
Lindsay Chatman
National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases
Author Profile
Megan C. Grieco
National Institute of Allergy and Infectious Diseases Biostatistics Research Branch
Author Profile
Carolyn H. Baloh
Brigham and Women's Faulkner Hospital
Author Profile
Michelle F Huffaker
Immune Tolerance Network
Author Profile
Lisa Wheatley
National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases
Author Profile
George Du Toit
King's College London School of Immunology & Microbial Sciences
Author Profile
Gideon Lack
King's College London School of Immunology & Microbial Sciences
Author Profile
Erica Brittain
National Institute of Allergy and Infectious Diseases Biostatistics Research Branch
Author Profile
Pamela Guerrerio
National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases
Author Profile

Abstract

Background: Intestinal barrier dysfunction may lead to a break in tolerance and development of food allergy (FA). There is contradictory evidence on whether intestinal permeability (IP) is altered in IgE-mediated FA. Thus, we sought to determine whether IP differed between children with eczema who did (FA group) or did not (atopic controls, ACs) develop FA and whether peanut sensitization, allergy and early introduction impacted IP using serum biomarkers zonulin, soluble CD14, and Intestinal Fatty Acid Binding Protein among randomly selected participants enrolled in the Learning Early About Peanut allergy trial. Methods: FA group was defined as having at least one FA at either baseline (4-11 months) or 60 months of age (V60). ACs had eczema at baseline and no FA at either visit. Serum IP markers (sIPMs) were measured by ELISA at baseline and V60 and their relationship with clinical characteristics of participants were analyzed using parametric tests and linear regression models. Results: We evaluated 237 FA subjects and 76 ACs. sIPM levels were similar in FA subjects and ACs at baseline and V60. Age when the child first developed any FA (<1 year vs >1 year), eczema severity, peanut sensitization, peanut allergy, and early peanut introduction were not statistically significantly associated with sIPM levels. Total IgE and eosinophil levels, peanut-specific IgE, IgG4 and IgG4/IgE ratio were not correlated with sIPM levels. Conclusion: No differences in sIPMs were detected to support altered IP in infants with FA compared to ACs or following early peanut introduction among peanut sensitized children.
Submitted to Allergy
Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned
27 Jun 2024Review(s) Completed, Editorial Evaluation Pending
17 Jul 2024Editorial Decision: Revise Minor
14 Nov 20241st Revision Received
18 Nov 2024Submission Checks Completed
18 Nov 2024Assigned to Editor
18 Nov 2024Review(s) Completed, Editorial Evaluation Pending
18 Nov 2024Reviewer(s) Assigned